Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ARDX

Ardelyx Inc

Feb 09 • 04:00PM ET

7.33

+0.01 0.14 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN REGN VRTX NBIX ENTA BMRN EXEL AKTX SRPT IRWD

| Held by: XBI IWM VTI VXF IWO SCHA FYC VTWO VHT FYX

Index	RUT	P/E	-	EPS (ttm)	-0.24	Insider Own	4.19%	Shs Outstand	242.97M	Perf Week	-5.91%
Market Cap	1.78B	Forward P/E	39.21	EPS next Y	0.19	Insider Trans	-2.84%	Shs Float	232.79M	Perf Month	4.71%
Enterprise Value	1.75B	PEG	-	EPS next Q	0.01	Inst Own	69.44%	Short Float	9.38%	Perf Quarter	29.73%
Income	-56.55M	P/S	4.47	EPS this Y	-42.63%	Inst Trans	-0.42%	Short Ratio	5.36	Perf Half Y	40.69%
Sales	398.23M	P/B	11.54	EPS next Y	177.10%	ROA	-13.24%	Short Interest	21.83M	Perf YTD	25.73%
Book/sh	0.63	P/C	7.34	EPS next 5Y	-	ROE	-36.18%	52W High	8.40 -12.74%	Perf Year	29.28%
Cash/sh	1.00	P/FCF	-	EPS past 3/5Y	52.14% 35.34%	ROIC	-15.69%	52W Low	3.21 128.35%	Perf 3Y	138.76%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	220.89% 129.14%	Gross Margin	87.54%	Volatility	5.17% 6.04%	Perf 5Y	5.32%
Dividend TTM	-	EV/Sales	4.38	EPS Y/Y TTM	24.08%	Oper. Margin	-9.53%	ATR (14)	0.41	Perf 10Y	-29.59%
Dividend Ex-Date	-	Quick Ratio	4.11	Sales Y/Y TTM	58.12%	Profit Margin	-14.20%	RSI (14)	52.59	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.41	EPS Q/Q	-17.65%	SMA20	-2.38%	Beta	0.59	Target Price	14.70
Payout	-	Debt/Eq	1.35	Sales Q/Q	12.30%	SMA50	11.43%	Rel Volume	0.49	Prev Close	7.32
Employees	395	LT Debt/Eq	1.34	Earnings	Feb 19 AMC	SMA200	36.42%	Avg Volume	4.08M	Price	7.33
IPO	Jun 19, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	100.00% 9.73%	Trades		Volume	2,012,812	Change	0.14%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-09-26	Upgrade	Piper Sandler	Neutral → Overweight
Sep-03-25	Resumed	Raymond James	Strong Buy	$14
Jun-18-25	Resumed	H.C. Wainwright	Buy	$10
May-02-25	Downgrade	Raymond James	Strong Buy → Outperform	$11
Mar-07-25	Resumed	Ladenburg Thalmann	Buy
Mar-04-25	Initiated	BTIG Research	Buy	$14
Nov-11-24	Downgrade	H.C. Wainwright	Buy → Neutral	$11 → $5.50
Jul-02-24	Downgrade	Piper Sandler	Overweight → Neutral	$15 → $7
Apr-05-24	Initiated	Leerink Partners	Outperform	$14
Dec-18-23	Initiated	Raymond James	Strong Buy	$12
Sep-07-23	Initiated	H.C. Wainwright	Buy	$9
Aug-25-23	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$5 → $10
Mar-03-23	Upgrade	Wedbush	Neutral → Outperform	$3 → $6
Nov-17-22	Upgrade	Piper Sandler	Neutral → Overweight	$3 → $8
May-06-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$7 → $1
Dec-01-21	Upgrade	Ladenburg Thalmann	Neutral → Buy	$6
Oct-14-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Jul-21-21	Downgrade	Jefferies	Buy → Hold	$11 → $2
Jul-20-21	Downgrade	Wedbush	Outperform → Neutral	$3
Jul-20-21	Downgrade	Piper Sandler	Overweight → Neutral	$14 → $4

Show Previous Ratings

Feb-05-26 08:00AM	Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026 (GlobeNewswire) -5.15%
Feb-04-26 08:41AM	Ardelyx receives new patent for Tenapanor (TipRanks)
Feb-03-26 08:29AM	Ardelyx Receives New Patent for Tenapanor (GlobeNewswire)
Feb-02-26 09:38AM	Ardelyx, Inc. (ARDX) Gains TD Analysts Support Ahead of Q4 Results (Insider Monkey)
Jan-30-26 09:47AM	Jefferies Remains a Buy on Ardelyx (ARDX) (Insider Monkey)
08:29AM	Loading…
Jan-28-26 08:29AM	First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA (GlobeNewswire)
Jan-26-26 12:00PM	All You Need to Know About Ardelyx (ARDX) Rating Upgrade to Buy (Zacks)
10:16AM	Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets (PR Newswire)
Jan-21-26 07:17AM	Strength Seen in Ardelyx (ARDX): Can Its 15.0% Jump Turn into More Strength? (Zacks)
Jan-12-26 09:40AM	Are Medical Stocks Lagging Ardelyx (ARDX) This Year? (Zacks)
Jan-08-26 08:30AM	Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook (GlobeNewswire) +20.07%
Jan-06-26 09:55AM	Wall Street Analysts See a 92.12% Upside in Ardelyx (ARDX): Can the Stock Really Move This High? (Zacks) -8.70%
Jan-05-26 08:43AM	When Does Changing Course Become Securities Fraud? Court Rules Against Ardelyx Shareholders (TipRanks)
08:25AM	Ardelyx (ARDX) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Nov-18-25 05:07AM	BTIG Maintains a Buy on Ardelyx, Inc (ARDX) (Insider Monkey)
04:05PM	Loading…
Nov-07-25 04:05PM	Real-World Evidence Studies of XPHOZAH (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week (GlobeNewswire)
Nov-05-25 08:00AM	Ardelyx to Participate at the Jefferies Global Healthcare Conference in London (GlobeNewswire) +6.25%
Nov-04-25 08:00AM	Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference (GlobeNewswire) -5.41%
Oct-30-25 11:03PM	Ardelyx Inc (ARDX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Market Challenges (GuruFocus.com) +20.96%
06:30PM	Ardelyx (ARDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:40PM	Ardelyx (ARDX) Reports Break-Even Earnings for Q3 (Zacks)
04:44PM	Ardelyx: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-28-25 08:01AM	Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA (tenapanor) at the American College of Gastroenterology's 2025 Annual Meeting (GlobeNewswire)
Oct-21-25 08:00AM	Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney Week (GlobeNewswire)
Oct-16-25 07:30AM	2 Overlooked Stocks to Snap Up in 2025 (Barchart)
Oct-13-25 08:35AM	Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025 (GlobeNewswire)
08:30AM	Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer (GlobeNewswire)
Sep-24-25 07:30AM	Is This Under-$10 Stock the Next Big Biotech Winner? (Barchart)
Aug-29-25 05:10AM	Ardelyx, Inc. (ARDX) Strengthens Global Reach with Kyowa Kirin Deal (Insider Monkey)
08:00AM	Loading…
Aug-25-25 08:00AM	Ardelyx to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-25 08:00AM	Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors (Business Wire)
Aug-05-25 03:04AM	Ardelyx Inc (ARDX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ... (GuruFocus.com) +16.86%
Aug-04-25 06:30PM	Ardelyx (ARDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:30PM	Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:30PM	Ardelyx: Q2 Earnings Snapshot (Associated Press Finance)
04:08PM	Ardelyx Announces Changes to the Executive Leadership Team (GlobeNewswire)
04:01PM	Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
10:01AM	Piper Sandler Maintains a Hold Rating on Ardelyx (ARDX) (Insider Monkey)
Jul-29-25 10:00AM	Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-28-25 10:00AM	Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline (Zacks)
Jul-23-25 11:25AM	Ardelyx (ARDX) Announced New data for IBSRELA (Insider Monkey)
Jul-21-25 08:00AM	Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025 (GlobeNewswire)
Jul-15-25 07:30AM	This Small-Cap Stock Could 10x by 2030, But Its Not for the Faint of Heart (Barchart)
Jul-07-25 09:10AM	Jefferies Maintains a Buy Rating on Ardelyx (ARDX) With an $8 Price Target (Insider Monkey)
Jul-01-25 04:00AM	A biopharma doubles down on diversity goals through a newly created position (Pharma Voice)
04:00AM	A biopharma bolsters patient centricity and trial diversity goals through newly created role (Pharma Voice)
Jun-29-25 03:00AM	Two Beaten-Down Biotech Stocks See Big Insider Buys (Barrons.com)
Jun-25-25 01:01PM	H.C. Wainwright Initiates Coverage of Ardelyx (ARDX) Stock, Gives Buy (Insider Monkey)
Jun-24-25 03:51PM	Leerink Partners Maintains a Buy Rating on Ardelyx (ARDX) With a $10 PT (Insider Monkey)
Jun-02-25 04:05PM	Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer (GlobeNewswire)
May-21-25 08:00AM	Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025 (GlobeNewswire)
May-06-25 08:01AM	Ardelyx Presents Data Supporting IBSRELA (tenapanor) at Digestive Disease Week 2025 Conference (GlobeNewswire) +5.76%
May-02-25 10:07AM	Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty (Seeking Alpha) -24.50%
07:30AM	Q1 2025 Ardelyx Inc Earnings Call (Thomson Reuters StreetEvents)
03:16AM	Ardelyx Inc (ARDX) Q1 2025 Earnings Call Highlights: Robust Revenue Growth Amid Market Challenges (GuruFocus.com)
May-01-25 10:06PM	Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:00PM	Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics (Zacks)
05:35PM	Ardelyx (ARDX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:29PM	Ardelyx: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-29-25 08:00AM	Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors (GlobeNewswire)
Apr-24-25 08:01AM	Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference (GlobeNewswire)
Apr-17-25 08:00AM	Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025 (GlobeNewswire)
Apr-16-25 11:21AM	Is Ardelyx Inc. (NASDAQ:ARDX) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey)
Apr-10-25 04:02PM	Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings (GlobeNewswire) -5.56%
Mar-31-25 04:03PM	Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH (tenapanor) at the National Kidney Foundation Spring Clinical Meetings (GlobeNewswire)
Mar-13-25 08:02AM	Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award (GlobeNewswire)
Feb-26-25 07:00AM	Tenapanor Approved in China for Hyperphosphatemia (GlobeNewswire)
Feb-25-25 04:15PM	Ardelyx to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-21-25 02:05AM	Ardelyx Inc (ARDX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Challenges (GuruFocus.com) -11.54%
Feb-20-25 11:51PM	Q4 2024 Ardelyx Inc Earnings Call (Thomson Reuters StreetEvents) -10.06%
09:30AM	Ardelyx (ARDX) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:45AM	Ardelyx (ARDX) Meets Q4 Earnings Estimates (Zacks)
07:52AM	Ardelyx: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-19-25 08:01AM	Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-13-25 10:01AM	Ardelyx (ARDX) Earnings Expected to Grow: Should You Buy? (Zacks)
Jan-30-25 04:30PM	Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025 (GlobeNewswire)
Jan-23-25 01:41PM	Chairman David Mott Bets $1M on Ardelyx--Is This Biotech Stock Set to Skyrocket? (GuruFocus.com) +9.11%
Jan-14-25 09:07AM	Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last? (Zacks)
Jan-13-25 08:03AM	Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities (GlobeNewswire) +15.98%
Jan-06-25 08:00AM	Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-30-24 02:41PM	Why Ardelyx (ARDX) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Nov-20-24 08:00AM	Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-08-24 12:31PM	Ardelyx Responds to District Court Decision Granting Motion to Dismiss (GlobeNewswire) -20.53%
Nov-05-24 08:00AM	Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference (GlobeNewswire)
Nov-01-24 10:04AM	Q3 2024 Ardelyx Inc Earnings Call (Thomson Reuters StreetEvents)
03:18AM	Ardelyx Inc (ARDX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Growth Amidst ... (GuruFocus.com)
Oct-31-24 05:30PM	Compared to Estimates, Ardelyx (ARDX) Q3 Earnings: A Look at Key Metrics (Zacks)
05:15PM	Ardelyx (ARDX) Reports Break-Even Earnings for Q3 (Zacks)
04:22PM	Ardelyx: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-28-24 04:05PM	Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology's (ACG) Annual Meeting (GlobeNewswire)
Oct-24-24 04:05PM	Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH (tenapanor) at the American Society of Nephrology's Kidney Week (GlobeNewswire) +5.02%
10:01AM	Earnings Preview: Ardelyx (ARDX) Q3 Earnings Expected to Decline (Zacks)
Oct-22-24 04:05PM	Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community (GlobeNewswire)
Oct-21-24 04:05PM	Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community (GlobeNewswire)
Oct-18-24 09:55AM	Here's Why Ardelyx (ARDX) Could be Great Choice for a Bottom Fisher (Zacks)
Oct-17-24 08:00AM	Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024 (GlobeNewswire)

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Williams Laura A	Chief Patient Officer	Jan 08 '26	Option Exercise	0.99	50,000	49,500	409,896	Jan 09 06:59 PM
Williams Laura A	Chief Patient Officer	Jan 08 '26	Sale	6.98	50,000	348,900	361,563	Jan 09 06:59 PM
LAURA A WILLIAMS	Officer	Jan 08 '26	Proposed Sale	5.83	50,000	291,500		Jan 08 04:25 PM
GRAMMER ELIZABETH A	See Remarks	Nov 21 '25	Sale	5.54	5,995	33,194	299,895	Nov 25 04:44 PM
RAAB MICHAEL	President & CEO	Nov 21 '25	Sale	5.54	46,887	259,609	1,455,363	Nov 25 04:42 PM
Kelliher Mike	See Remarks	Nov 21 '25	Sale	5.54	5,560	30,785	271,181	Nov 25 04:38 PM
Williams Laura A	Chief Patient Officer	Nov 21 '25	Sale	5.54	6,426	35,580	359,896	Nov 25 04:35 PM
Foster Eric Duane	Chief Commercial Officer	Nov 21 '25	Sale	5.54	5,814	32,192	295,684	Nov 25 04:22 PM
Reilly Joseph James	See Remarks	Nov 21 '25	Sale	5.54	11,086	61,382	108,914	Nov 25 04:21 PM
Renz Justin A	Former Officer	Nov 24 '25	Proposed Sale	5.55	49,040	272,172		Nov 24 06:03 PM
Williams Laura A	Officer	Nov 20 '25	Proposed Sale	5.91	6,354	37,552		Nov 20 05:46 PM
RAAB MICHAEL	Officer	Nov 20 '25	Proposed Sale	5.91	45,868	271,080		Nov 20 05:35 PM
Kelliher Mike	Officer	Nov 20 '25	Proposed Sale	5.91	5,433	32,109		Nov 20 05:23 PM
Reilly Joseph James	Officer	Nov 20 '25	Proposed Sale	5.91	10,845	64,094		Nov 20 05:06 PM
GRAMMER ELIZABETH A	Officer	Nov 20 '25	Proposed Sale	5.91	5,851	34,579		Nov 20 05:00 PM
Foster Eric Duane	Officer	Nov 20 '25	Proposed Sale	5.91	5,502	32,517		Nov 20 04:51 PM
Williams Laura A	Chief Patient Officer	Aug 26 '25	Option Exercise	0.99	50,000	49,500	446,322	Aug 28 07:30 PM
Williams Laura A	Chief Patient Officer	Aug 26 '25	Sale	6.12	80,000	489,680	366,322	Aug 28 07:30 PM
Kelliher Mike	Chief Business Officer	Aug 21 '25	Sale	5.93	5,417	32,132	276,741	Aug 28 07:29 PM
LAURA A WILLIAMS	Officer	Aug 26 '25	Proposed Sale	6.06	80,000	484,800		Aug 26 04:29 PM
Williams Laura A	Chief Patient Officer	Aug 21 '25	Sale	5.93	6,261	37,138	396,322	Aug 25 09:13 PM
Renz Justin A	Chief Financial Officer	Aug 21 '25	Sale	5.93	7,037	41,741	409,052	Aug 25 09:12 PM
RAAB MICHAEL	President & CEO	Aug 21 '25	Sale	5.93	45,687	271,002	1,502,250	Aug 25 09:08 PM
GRAMMER ELIZABETH A	See Remarks	Aug 21 '25	Sale	5.93	5,841	34,647	305,890	Aug 25 09:03 PM
Foster Eric Duane	Chief Commercial Officer	Aug 21 '25	Sale	5.93	15,308	90,802	301,498	Aug 25 09:02 PM
MOTT DAVID M	Director	Jun 16 '25	Buy	3.63	200,000	725,880	2,896,871	Jun 18 09:28 PM
MOTT DAVID M	Director	Jun 09 '25	Buy	3.69	200,000	737,260	2,696,871	Jun 11 09:40 PM
Williams Laura A	Chief Medical Officer	May 20 '25	Sale	4.08	6,421	26,207	402,583	May 22 09:55 PM
Renz Justin A	Chief Financial Officer	May 20 '25	Sale	4.08	7,218	29,460	416,089	May 22 09:53 PM
RAAB MICHAEL	President & CEO	May 20 '25	Sale	4.08	46,817	191,079	1,547,937	May 22 09:52 PM
Kelliher Mike	See Remarks	May 20 '25	Sale	4.08	14,522	59,270	282,158	May 22 09:51 PM
GRAMMER ELIZABETH A	See Remarks	May 20 '25	Sale	4.08	5,992	24,456	311,731	May 22 09:50 PM
Foster Eric Duane	Chief Commercial Officer	May 20 '25	Sale	4.08	2,507	10,232	316,806	May 22 09:49 PM
MOTT DAVID M	Director	May 15 '25	Buy	3.29	100,000	329,120	2,496,871	May 19 05:02 PM
MOTT DAVID M	Director	May 02 '25	Buy	4.22	381,377	1,610,936	2,396,871	May 05 08:22 PM
RAAB MICHAEL	President & CEO	May 02 '25	Option Exercise	0.99	20,833	20,625	1,636,420	May 05 08:14 PM
RAAB MICHAEL	President & CEO	May 02 '25	Sale	4.25	41,666	177,168	1,594,754	May 05 08:14 PM
MICHAEL RAAB	Director	May 02 '25	Proposed Sale	5.47	125,000	683,750		May 02 04:22 PM
RAAB MICHAEL	President & CEO	Apr 04 '25	Option Exercise	0.99	20,833	20,625	1,657,253	Apr 08 07:24 PM
RAAB MICHAEL	President & CEO	Apr 04 '25	Sale	4.59	41,666	191,151	1,615,587	Apr 08 07:24 PM
Rosenbaum David P.	Officer	Mar 17 '25	Proposed Sale	5.47	44,330	242,559		Mar 17 05:40 PM
RAAB MICHAEL	President & CEO	Mar 07 '25	Option Exercise	0.99	20,834	20,626	1,676,806	Mar 07 07:25 PM
RAAB MICHAEL	President & CEO	Mar 07 '25	Sale	5.36	41,668	223,199	1,635,138	Mar 07 07:25 PM
MOTT DAVID M	Director	Feb 24 '25	Buy	5.00	77,729	388,738	2,015,494	Feb 26 07:21 PM
Williams Laura A	Chief Medical Officer	Feb 20 '25	Sale	5.62	4,941	27,783	303,804	Feb 21 06:56 PM
Renz Justin A	Chief Financial Officer	Feb 20 '25	Sale	5.62	5,171	29,077	285,968	Feb 21 06:55 PM
RAAB MICHAEL	President & CEO	Feb 20 '25	Sale	5.62	22,964	129,124	1,085,755	Feb 21 06:54 PM
GRAMMER ELIZABETH A	See Remarks	Feb 20 '25	Sale	5.62	4,291	24,128	181,043	Feb 21 06:53 PM
Blanks Robert	Officer	Feb 12 '25	Proposed Sale	5.46	75,000	409,765		Feb 12 05:58 PM

Open in Screener

FOLD

Amicus Therapeutics Inc

Feb 09 • 04:00PM ET

14.30

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

FOLD Amicus Therapeutics Inc daily Stock Chart

Peers: VRTX SRPT BMRN REGN CRSP EDIT PFE QURE AGIO BLUE

| Held by: VTI XBI IWM VB VBK VXF IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-0.04	Insider Own	1.77%	Shs Outstand	308.50M	Perf Week	0.07%
Market Cap	4.49B	Forward P/E	50.05	EPS next Y	0.29	Insider Trans	-7.60%	Shs Float	308.16M	Perf Month	0.14%
Enterprise Value	4.66B	PEG	-	EPS next Q	0.07	Inst Own	98.96%	Short Float	6.29%	Perf Quarter	60.67%
Income	-14.06M	P/S	7.49	EPS this Y	92.06%	Inst Trans	-3.29%	Short Ratio	1.78	Perf Half Y	111.54%
Sales	598.70M	P/B	19.15	EPS next Y	2099.96%	ROA	-1.70%	Short Interest	19.39M	Perf YTD	0.42%
Book/sh	0.75	P/C	17.00	EPS next 5Y	-	ROE	-6.87%	52W High	14.38 -0.56%	Perf Year	45.47%
Cash/sh	0.84	P/FCF	462.95	EPS past 3/5Y	41.55% 34.10%	ROIC	-2.12%	52W Low	5.51 159.53%	Perf 3Y	5.85%
Dividend Est.	-	EV/EBITDA	110.75	Sales past 3/5Y	20.03% 23.72%	Gross Margin	88.50%	Volatility	0.22% 0.24%	Perf 5Y	-28.96%
Dividend TTM	-	EV/Sales	7.79	EPS Y/Y TTM	87.30%	Oper. Margin	5.77%	ATR (14)	0.09	Perf 10Y	133.28%
Dividend Ex-Date	-	Quick Ratio	2.09	Sales Y/Y TTM	21.28%	Profit Margin	-2.35%	RSI (14)	79.35	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.99	EPS Q/Q	352.49%	SMA20	0.01%	Beta	0.43	Target Price	14.50
Payout	-	Debt/Eq	1.92	Sales Q/Q	19.46%	SMA50	10.31%	Rel Volume	0.39	Prev Close	14.30
Employees	499	LT Debt/Eq	1.88	Earnings	Nov 04 BMO	SMA200	64.09%	Avg Volume	10.91M	Price	14.30
IPO	May 31, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	55.44% 2.02%	Trades		Volume	4,301,300	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-22-26	Downgrade	Jefferies	Buy → Hold	$14.50
Dec-29-25	Downgrade	Leerink Partners	Outperform → Market Perform	$14.50
Dec-22-25	Downgrade	TD Cowen	Buy → Hold	$14.50
Dec-17-25	Initiated	Citigroup	Buy	$17
Sep-18-25	Upgrade	Needham	Hold → Buy	$14
Jul-17-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$108
Dec-13-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$17 → $12
Sep-06-24	Initiated	Jefferies	Buy	$18
May-30-24	Initiated	Wells Fargo	Overweight	$18
May-14-24	Upgrade	Guggenheim	Neutral → Buy	$13
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$15 → $20
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$14
Apr-13-22	Resumed	Goldman	Neutral	$11
Jan-14-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$12 → $16
Nov-15-21	Upgrade	Stifel	Hold → Buy	$12 → $16
Sep-30-21	Upgrade	JP Morgan	Neutral → Overweight	$16
Jul-19-21	Resumed	BTIG Research	Buy	$15
May-27-21	Initiated	Needham	Hold
May-21-21	Initiated	UBS	Buy	$16
Apr-14-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$17

Show Previous Ratings

Feb-03-26 08:00AM	Amicus Therapeutics Presents New Long-term Data for both Galafold (migalastat) and POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat) at the 22nd Annual WORLDSymposium 2026 (GlobeNewswire)
Feb-02-26 09:29AM	Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments (Insider Monkey)
Jan-28-26 11:24AM	FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside? (Zacks)
Jan-23-26 07:18AM	JANX Enters Global Oncology Collaboration With BMY, Stock Rises (Zacks)
Jan-22-26 11:55AM	Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema (Zacks)
08:00AM	Loading…
08:00AM	Here Are Thursdays Top Wall Street Analyst Research Calls: Alphabet, Callaway Golf, Datadog, Hyatt Hotels, Palantir, Texas Instruments, Verizon, and More (24/7 Wall St.)
Jan-21-26 10:46AM	ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission (Zacks)
10:12AM	NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies (Zacks)
08:36AM	MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know (Zacks)
Jan-19-26 12:53PM	Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease (Zacks)
08:01AM	Beat the Market the Zacks Way: Amicus, Micron, Amgen in Focus (Zacks)
Jan-16-26 11:15AM	Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia (Zacks)
11:01AM	FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? (Zacks)
09:06AM	Erasca Stock Surges 42% in a Week: Here's What You Should Know (Zacks)
Jan-15-26 11:16AM	Apellis Stock Crashes 23% in a Week: Here's What You Should Know (Zacks)
10:26AM	Loading…
10:26AM	CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why (Zacks)
06:47AM	One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit (24/7 Wall St.)
Jan-14-26 10:52AM	TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results (Zacks)
10:18AM	PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific (Zacks)
Jan-13-26 01:28PM	ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook (Zacks)
09:19AM	Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes (Zacks)
Jan-12-26 02:07PM	KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives (Zacks)
11:20AM	MDGL Secures Exclusive Global Right for MASH Treatment From PFE (Zacks)
10:14AM	PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates (Zacks)
09:33AM	Exelixis Posts Preliminary '25 Results, Issues '26 Outlook (Zacks)
Jan-09-26 11:46AM	AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations (Zacks)
09:17AM	Bayer Accelerates Growth With siRNA, AI Deals and Pipeline Progress (Zacks)
Jan-08-26 12:49PM	Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
11:09AM	GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug (Zacks)
09:44AM	KRYS Stock Surges 57% in a Year: More Upside Potential in 2026? (Zacks)
08:50AM	Loading…
08:50AM	EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study (Zacks)
Jan-07-26 09:53AM	OTLK Stock Crashes 67% in a Week: Here's What You Need to Know (Zacks)
Jan-06-26 11:47AM	Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase? (Zacks)
11:15AM	Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings? (Zacks)
10:50AM	Halper Sadeh LLC Encourages DBRG, FOLD, DVAX Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Jan-02-26 01:13PM	When healthcare M&A hits the cold chain (FreightWaves)
Dec-30-25 10:19AM	Halper Sadeh LLC Encourages EKSO, FOLD, WBD, CFLT Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Dec-29-25 07:52AM	Here Are Mondays Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More (24/7 Wall St.)
Dec-23-25 06:45PM	Halper Sadeh LLC Encourages KPLT, FOLD, DHIL Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Dec-22-25 12:27PM	BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push (Pharmaceutical Technology)
12:15PM	A $4.8 Billion Reason to Buy BioMarin Stock Today (Barchart)
11:46AM	BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B (Zacks)
09:47AM	Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls (The Fly)
09:29AM	Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up (Zacks)
Dec-20-25 08:12AM	Amicus (FOLD) Flies to 52-Week High on $5-Billion BioMarin Merger (Insider Monkey)
Dec-19-25 04:32PM	Stocks to Watch Friday Recap: Lamb Weston, Intuitive Machines, Nike, Oracle (The Wall Street Journal) +30.21%
04:17PM	BioMarin Soars 18% After Folding In The $4.8 Billion Takeover Of Amicus (Investor's Business Daily)
12:41PM	Biotech Bombshell: BioMarin's $4.8B Bet Ignites Amicus Shares in Rare-Disease Power Play (GuruFocus.com)
12:17PM	Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates (Zacks)
11:57AM	BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion (The Wall Street Journal)
11:01AM	Stocks to Watch Friday: Lamb Weston, Intuitive Machines, Nike, Oracle (The Wall Street Journal)
10:55AM	BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping. (Barrons.com)
09:38AM	Stocks to Watch Friday: Nike, Oracle, FedEx, Sony (The Wall Street Journal)
09:33AM	BioMarin Pharmaceutical Scoops Up Amicus Therapeutics In $4.8 Billion Deal (Investor's Business Daily)
08:13AM	BioMarin to Buy Amicus Therapeutics for $4.8 Billion (The Wall Street Journal)
07:45AM	BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook (PR Newswire)
Dec-18-25 03:43AM	Zacks Industry Outlook Arcutis, Amicus and ANI (Zacks)
Dec-17-25 02:19PM	5 Biotech Stocks to Watch for Potential Upside (Zacks)
Dec-16-25 10:30AM	FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock? (Zacks)
08:53AM	GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal (Zacks)
Dec-15-25 09:59AM	RCUS Stock Down on Decision to Discontinue GILD Partnered Study (Zacks)
Dec-13-25 07:05AM	Amicus Therapeutics (FOLD) Soars to 52-Week High on 'Strong Buy' Reco (Insider Monkey)
Dec-12-25 09:55AM	Wall Street Analysts See a 60.61% Upside in Amicus Therapeutics (FOLD): Can the Stock Really Move This High? (Zacks) +6.57%
Dec-09-25 01:48PM	The Best Cheap Stocks Under $10 to Buy in December and 2026 (Zacks)
Dec-08-25 08:23AM	Beat the Market the Zacks Way: Veracyte, Las Vegas Sands, 3M in Focus (Zacks)
Dec-05-25 12:20PM	Surging Earnings Estimates Signal Upside for Amicus Therapeutics (FOLD) Stock (Zacks)
09:57AM	Can Galafold Continue to Drive Amicus' Top Line in 2026? (Zacks)
Dec-04-25 11:30AM	Amicus Therapeutics (FOLD) Up 6.4% Since Last Earnings Report: Can It Continue? (Zacks)
10:29AM	BMY Gains on News of Continuation of Alzheimer's Disease Study (Zacks)
Dec-02-25 02:20PM	BHC Stock Up as Solta Acquires Shibo's Aesthetics Distribution Business (Zacks)
Nov-26-25 09:55AM	Wall Street Analysts Think Amicus Therapeutics (FOLD) Could Surge 58.46%: Read This Before Placing a Bet (Zacks)
Nov-25-25 02:00PM	FDA Greenlights Novartis' Gene Replacement Treatment for SMA (Zacks)
Nov-24-25 01:53PM	BAYRYs Cardiovascular Drug Hits Goals in Late-Stage Study (Zacks)
Nov-21-25 10:15AM	NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth (Zacks)
Nov-19-25 08:53AM	BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU (Zacks)
Nov-14-25 08:11AM	GILD's Investigational Regimen for HIV Treatment Meets Primary Goal (Zacks)
Nov-13-25 01:46PM	Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth? (Zacks)
Nov-11-25 12:52PM	Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus (Zacks)
Nov-10-25 08:16PM	Goldman Sachs Bullish on Amicus Therapeutics (FOLD) Following Q3 2025 Results (Insider Monkey)
09:55AM	Wall Street Analysts Believe Amicus Therapeutics (FOLD) Could Rally 76.32%: Here's is How to Trade (Zacks)
01:44AM	Zacks.com featured highlights include EverQuote, Amicus, Lam Research and Cboe Global Markets EverQuote, Amicus, Lam Research and Cboe Global Markets (Zacks)
Nov-07-25 10:40AM	Bet on These 4 Top-Performing Liquid Stocks to Maximize Returns (Zacks)
Nov-06-25 10:43AM	Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
10:24AM	Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance (Zacks)
09:24AM	RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y (Zacks)
08:27AM	ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales (Zacks)
Nov-05-25 10:52AM	EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales (Zacks)
10:48AM	Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y (Zacks)
10:41AM	Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up (Zacks)
10:30AM	Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles (Zacks)
10:08AM	Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues (Zacks)
09:30AM	Compared to Estimates, Amicus Therapeutics (FOLD) Q3 Earnings: A Look at Key Metrics (Zacks)
Nov-04-25 04:07PM	Amicus Therapeutics Inc (FOLD) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
11:43AM	ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down (Zacks)
09:54AM	Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
08:35AM	Amicus Therapeutics (FOLD) Beats Q3 Earnings and Revenue Estimates (Zacks)
07:29AM	Amicus Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Oct-31-25 01:45PM	Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates (Zacks)
10:37AM	ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales (Zacks)

Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Campbell Bradley L	President and CEO	Jan 20 '26	Option Exercise	6.10	75,000	457,500	1,096,180	Jan 22 07:26 PM
Campbell Bradley L	President and CEO	Jan 20 '26	Sale	14.31	75,000	1,073,182	1,021,180	Jan 22 07:26 PM
BRADLEY CAMPBELL	Director	Jan 20 '26	Proposed Sale	14.33	75,000	1,074,750		Jan 20 04:26 PM
Clark David Michael	Chief People Officer	Dec 19 '25	Sale	14.17	25,642	363,380	245,690	Dec 23 04:16 PM
DAVID CLARK	Officer	Dec 19 '25	Proposed Sale	10.89	25,642	279,241		Dec 19 04:22 PM
Campbell Bradley L	President and CEO	Dec 15 '25	Option Exercise	9.03	70,426	635,947	1,207,708	Dec 17 06:21 PM
Campbell Bradley L	President and CEO	Dec 15 '25	Sale	10.86	77,926	846,011	1,129,782	Dec 17 06:21 PM
Clark David Michael	Chief People Officer	Dec 15 '25	Sale	11.00	25,643	282,073	271,332	Dec 17 06:19 PM
BRADLEY CAMPBELL	Director	Dec 15 '25	Proposed Sale	10.55	77,926	822,119		Dec 15 04:32 PM
DAVID CLARK	Officer	Dec 15 '25	Proposed Sale	10.55	25,643	270,534		Dec 15 04:17 PM
Campbell Bradley L	President and CEO	Dec 01 '25	Option Exercise	9.03	14,587	131,721	1,151,869	Dec 03 08:11 PM
Campbell Bradley L	President and CEO	Dec 01 '25	Sale	10.01	14,587	146,011	1,137,282	Dec 03 08:11 PM
BRADLEY CAMPBELL	Director	Dec 01 '25	Proposed Sale	9.93	14,587	144,849		Dec 01 04:19 PM
Castelli Jeff	Chief Development Officer	Nov 24 '25	Option Exercise	9.03	50,000	451,500	515,476	Nov 26 09:18 PM
Castelli Jeff	Chief Development Officer	Nov 24 '25	Sale	10.16	76,158	773,659	439,318	Nov 26 09:18 PM
Clark David Michael	Chief People Officer	Nov 24 '25	Sale	10.10	25,643	258,933	296,975	Nov 26 09:17 PM
Campbell Bradley L	President and CEO	Nov 24 '25	Option Exercise	9.03	14,587	131,721	1,151,869	Nov 26 09:17 PM
Campbell Bradley L	President and CEO	Nov 24 '25	Sale	10.04	14,587	146,522	1,137,282	Nov 26 09:17 PM
Rosenberg Ellen	Chief Legal Officer	Nov 24 '25	Option Exercise	5.80	36,000	208,930	543,710	Nov 26 09:16 PM
Rosenberg Ellen	Chief Legal Officer	Nov 25 '25	Option Exercise	5.13	36,000	184,680	543,710	Nov 26 09:16 PM
Rosenberg Ellen	Chief Legal Officer	Nov 26 '25	Option Exercise	5.13	23,621	121,176	531,331	Nov 26 09:16 PM
Rosenberg Ellen	Chief Legal Officer	Nov 24 '25	Sale	10.06	36,000	362,268	507,710	Nov 26 09:16 PM
Rosenberg Ellen	Chief Legal Officer	Nov 25 '25	Sale	10.00	36,000	360,000	507,710	Nov 26 09:16 PM
Rosenberg Ellen	Chief Legal Officer	Nov 26 '25	Sale	10.00	23,621	236,210	507,710	Nov 26 09:16 PM
ELLEN ROSENBERG	Officer	Nov 26 '25	Proposed Sale	9.87	23,621	233,139		Nov 26 04:18 PM
ELLEN ROSENBERG	Officer	Nov 25 '25	Proposed Sale	9.89	36,000	356,040		Nov 25 04:27 PM
JEFFREY CASTELLI	Officer	Nov 24 '25	Proposed Sale	9.56	76,158	728,070		Nov 24 04:25 PM
DAVID CLARK	Officer	Nov 24 '25	Proposed Sale	9.56	25,643	245,147		Nov 24 04:24 PM
BRADLEY CAMPBELL	Director	Nov 24 '25	Proposed Sale	9.56	14,587	139,452		Nov 24 04:24 PM
ELLEN ROSENBERG	Officer	Nov 24 '25	Proposed Sale	9.56	36,000	344,160		Nov 24 04:23 PM
Clark David Michael	Chief People Officer	Nov 04 '25	Sale	9.51	25,643	243,860	322,618	Nov 05 04:05 PM
DAVID CLARK	Officer	Nov 04 '25	Proposed Sale	8.86	25,643	227,197		Nov 04 04:33 PM
Campbell Bradley L	President and CEO	Feb 19 '25	Option Exercise	9.03	400	3,612	1,151,057	Feb 21 07:27 PM
Campbell Bradley L	President and CEO	Feb 19 '25	Sale	10.00	400	4,000	1,150,657	Feb 21 07:27 PM
BRADLEY CAMPBELL	Director	Feb 19 '25	Proposed Sale	9.85	400	3,940		Feb 19 04:36 PM

ARDX

Ardelyx Inc

FOLD

Amicus Therapeutics Inc

Upgrade your FINVIZ experience